Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy

This article was originally published in SRA

Executive Summary

Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.

You may also be interested in...

Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront

Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.

Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System

Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.

France Rejects Advice To Delay Second Dose Of Pfizer Vaccine

The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts